Application of intranasal butorphanol in painless gastroenteroscopy

Comparing the dose of propofol via different combinations of intranasal butorphanol, intravenous butorphanol or sufentanil in gastrointestinal endoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048028

Enrollment

Unknown

Registered

2021-06-28

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

intranasal butorphanol:1mg butorphanol spay

intravenous butorphanol:0.5mg butorphanol injection

sufentanil group:5ug sufentanil injiection

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years old; 2. BMI <=28kg/m2; 3. ASA grade I-II; 4. Patients who plan to undergo both gastroscopy and colonoscopy; 5. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindication to nasal administration (such as nasal cavity defect or lesion); 2. Body weight<40kg; 3. Severe heart, liver or kidney disease; 4. Previous history of severe motion sickness; 5. Patients who are allergic to drugs; 6. Patients with upper respiratory tract infection or using benzodiazepines and opioids in the past two weeks; 7. Exclusion of cases with interruption of gastroenteroscopy for any reason.

Design outcomes

Primary

Measure	Time frame
The dose of propofol;	—

Secondary

Measure	Time frame
Cough;Hypoxia;Modified Observer’s Alertness/Sedation scale;Discharge time;VAS score;Endoscopist satisfaction;Patient satisfaction;BMI;Heart rate;MAP;Blood oxygen saturation;Procedure duration;	—

Countries

China

Contacts

Public ContactGong Gu

General Hospital of the Western Theater of the Chinese people's Liberation Army

704682070@qq.com+86 13980525688

Outcome results